Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

2.860 -0.080 (-2.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier. 
Via Stocktwits
Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026. 
Via Benzinga
Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript
CMPS earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
This Plumas Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca. 
Via Stocktwits
Uncovering Potential: Compass Pathways's Earnings Preview
Via Benzinga
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks. 
Via Investor's Business Daily
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?
Don't jump in without doing some research first. 
Via The Motley Fool
COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co?
COMPASS Pathways faces $43M market cap loss, raising concerns among institutional investors holding 30% ownership. 
Via Benzinga
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
Via Benzinga
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Investor's Business Daily
Topics Government
Exposures Political
FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment
FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory hurdles. 
Via Benzinga
Exposures Product Safety
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Top 3 Health Care Stocks You'll Regret Missing In November
Via Benzinga
Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript
CMPS earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results
Via Benzinga
As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash
Compass Pathways delays key Phase 3 psilocybin trial readouts, triggering a 30% workforce reduction amid efforts to conserve cash and refocus. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Gains 1%; Meta Shares Fall Following Q3 Results
Via Benzinga
Exposures Fossil Fuels
Estée Lauder, Robinhood, eBay And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential. 
Via Benzinga
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
New study suggests psilocybin may help treat body dysmorphic disorder by rewiring brain connectivity and reducing obsessive thought patterns. 
Via Benzinga
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Via Benzinga
Exposures Product Safety
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
Shake Up At Lykos Therapeutics After FDA Blocks Ecstasy-Based Treatment, CEO Steps Down
Lykos Therapeutics CEO Amy Emerson steps down following the FDA's rejection of the company's MDMA-based PTSD therapy. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.